David Rosmarin, Scott Fretzin, Lindsay Strowd, Marta Casillas, Amy M DeLozier, Zach Dawson, Sherry Chen, Na Lu, Jacob P Thyssen
BACKGROUND: Skin pain (discomfort/soreness) is a common symptom associated with atopic dermatitis (AD). OBJECTIVE: To evaluate rapid changes in skin pain severity with baricitinib, and its impact on patient quality of life (QoL) in adults with moderate-to-severe AD who were inadequate responders to topical therapy. METHODS: Adult patients with moderate-to-severe AD who were inadequate responders to topical therapies ( N = 440, BREEZE-AD5 [NCT03435081]) were randomized to once-daily placebo, baricitinib 1 mg, or baricitinib 2 mg for 16 weeks...
March 31, 2022: Journal of Cutaneous Medicine and Surgery